Taisun Biotech Corrects Errors in Its Q1 2026 Consolidated Financial Report
NQ Score
3/100
N1 Content Completeness
2
AI Summary (NQ-processed)
On May 20, 2026, Taisun Biotechnology Co., Ltd. announced a correction to its Q1 2026 consolidated financial report due to clerical errors. The correction pertains to the cash flow statement, rectifying an incorrect sign for "Interest expense" and "Interest paid," and addressing the omission of "Interest income" and "Interest received." The corresponding iXBRL filing has also been corrected.